News | January 29, 2021
Laurus Q3 FY21 revenue up 76%; PAT grows 274%
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
The company is expecting tremendous growth and a better quarterly performance
Subscribe To Our Newsletter & Stay Updated
